

REMARKS

Objection to the Claims:

Claims 8, 17, 21, and 22 have been objected as being of improper dependent form.

Applicants have canceled the claims to obviate the rejection.

Rejection of the claims under 35 USC 103:

Claims 8, and 21 have been rejected under 35 U.S.C. 103(a) as being unpatentable over Wolff et al (WO 01/49841) in view of Oda et al. (Journal of the National Cancer Institute, Vol. 79, No. 6, p/ 1205-1211, 1987). The rejected claims have been canceled in response to the objection to the claims.

Claims 8, and 21 have been rejected under 35 U.S.C. 103(a) as being unpatentable over Wolff et al (WO 01/49841) in view of Sacttone et al. ("Inserts for Sustained Ocular Delivery of Pilocarpine: Evaluation of a Series of Partial Esters of (Maleic - Alkyl Vinyl Ether) Alternating Copolymers." Polymers in Medicine III: Third International Conference on Polymers in Medicine, Porto Cervo Italy, Ed. Migliarese, C., et al. Elsevier Science Publishers B. V., p. 209-224, 1998). The rejected claims have been canceled in response to the objection to the claims.

The Examiner's objections and rejections are now believed to be overcome by this response to the Office Action. The Action states that claims 5, 7, 12, and 16 are allowed. Applications have canceled the rejected claims.

Respectfully submitted,

/Kirk Ekena/
Kirk Ekena Reg. No. 56,672
Roche Madison Inc.
505 South Rosa Road
Madison, WI 53719
608-238-4400

I hereby certify that this correspondence is being transmitted to the USPTO on this date: 01/13/2010.

/Kirk Ekena/
Kirk Ekena